James Warneke

Professor, Surgery | Member of the Graduate Faculty

About

James A. Warneke, MD, FACS, is a professor in the Department of Surgery, Division of General Surgery. He joined the faculty at the University of Arizona's College of Medicine in the Department of Surgery, Section of Surgical Oncology in 1991.

Research Area

cancer, dermatology, clinical trials, tumor biology, coagulation, hemeoxygenase-1, colon cancer, pancreas cancer, fibrinolysis, tissue-type plasminogen activator

Targeted Prevention for Non-Melanoma Skin Cancer
Active·2019·$170.3K / $7.1M·
External
Co-Investigator (COI)
skin cancer, prevention, targeted therapy, non-melanoma, public health
Southwest Oncology Group CA13612
2010·$21.1K / $1.1M·
External
Co-Investigator (COI)
oncology, clinical trials, cancer research, medical research, healthcare

Recent

Neoadjuvant versus Adjuvant Pembrolizumab for Resectable Stage III-IV Melanoma br

2023

melanoma, immunotherapy, cancer treatment, clinical trials, surgical oncology

Protein activation mapping of human sun-protected epidermis after an acute dose of erythemic solar simulated light

2017

protein activation, epidermis response, solar light exposure, sun protection, erythemic response

Quantitative histopathology identifies patients with thin melanomas who are at risk for metastases

2016

histopathology, melanomas, metastases, quantitative analysis, patient risk assessment

Prognostic significance of lymph node yield in ypN0 rectal cancer

2016

cancer, lymph nodes, prognosis, rectal, surgery

Phase IIB Randomized Study of Topical Difluoromethylornithine and Topical Diclofenac on Sun-Damaged Skin of the Forearm

2015

skin research, clinical trial, dermatology, pharmacology, sun damage

Activation of the PI3K/Akt/mTOR and MAPK Signaling Pathways in Response to Acute Solar-Simulated Light Exposure of Human Skin

2015

cell signaling, skin damage, photobiology, cancer biology, dermatology

Colon and pancreas tumors enhance coagulation: role of hemeoxygenase-1

2014

tumor biology, coagulation, hemeoxygenase-1, colon cancer, pancreas cancer

Tissue-type plasminogen activator-induced fibrinolysis is enhanced in patients with breast, lung, pancreas and colon cancer

2014

cancer, fibrinolysis, tissue-type plasminogen activator, breast cancer, lung cancer

A phase 2 trial of complete resection for stage IV melanoma: results of Southwest Oncology GrouClinical Trial S9430

2011

Multiple primary cutaneous melanomas in Li-Fraumeni syndrome

2011

Page 1 of 3

James Warneke

About

Research Area

Grants(2)

Targeted Prevention for Non-Melanoma Skin Cancer

Southwest Oncology Group CA13612

Publications(54)

Neoadjuvant versus Adjuvant Pembrolizumab for Resectable Stage III-IV Melanoma br

Protein activation mapping of human sun-protected epidermis after an acute dose of erythemic solar simulated light

Quantitative histopathology identifies patients with thin melanomas who are at risk for metastases

Prognostic significance of lymph node yield in ypN0 rectal cancer

Phase IIB Randomized Study of Topical Difluoromethylornithine and Topical Diclofenac on Sun-Damaged Skin of the Forearm

Activation of the PI3K/Akt/mTOR and MAPK Signaling Pathways in Response to Acute Solar-Simulated Light Exposure of Human Skin

Colon and pancreas tumors enhance coagulation: role of hemeoxygenase-1

Tissue-type plasminogen activator-induced fibrinolysis is enhanced in patients with breast, lung, pancreas and colon cancer

A phase 2 trial of complete resection for stage IV melanoma: results of Southwest Oncology GrouClinical Trial S9430

Multiple primary cutaneous melanomas in Li-Fraumeni syndrome

Collaborations(11)

Denise Roe

Baldassarre Stea

Dean Billheimer

Setsuko Chambers

Donato Romagnolo

News(2)

El Tour Full of Thrills (and Spills) for AHSC Employees

New Procedure for Analyzing Milk-Duct Cells May Provide Possible Early Warning Signs of Breast Cancer